Evidence map›Paper›PMID 39102108›Full record

ReviewMolecular neurobiology2025

Recent Insights into the Neurobiology of Alzheimer's Disease and Advanced Treatment Strategies.

Anitha K, Mandeep Kumar Singh, Komal Kohat, Sri Varshini T, Santenna Chenchula, Padmavathi R, Lakshmi Sahitya Amerneni, Vishnu Vardhan K, Mythili Bai K, Madhav Rao Chavan and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anitha KSchool of Pharmacy and Technology Management (SPTM), SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed to University, Shirpur, 425405, India.
Mandeep Kumar SinghAmity Institute of Pharmacy, Amity University, Gwalior, India.
Komal KohatAll India Institute of Medical Sciences, Madhya Pradesh, Bhopal, 462020, India.
Sri Varshini TAll India Institute of Medical Sciences, Raipur, 462020, India.
Santenna ChenchulaDepartment of Pharmacology, All India Institute of Medical Sciences, Bhopal, 462020, India. csanten7@gmail.com.
Padmavathi RSVS Medical College, Hyderabad, Telangana, India.
Lakshmi Sahitya AmerneniGuntur Medical College, Guntur, Andhra Pradesh, India.
Vishnu Vardhan KAll India Institute of Medical Sciences, Madhya Pradesh, Bhopal, 462020, India.
Mythili Bai KSiddhartha Medical College, Vijayawada, India.
Madhav Rao ChavanAll India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India.
Shvetank BhattSchool of Health Sciences and Technology, MIT World Peace University, Dr. Vishwanath Karad, Pune, 411038, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, significant advancements have been made in understanding Alzheimer's disease from both neurobiological and clinical perspectives. Exploring the complex systems underlying AD has unveiled insights that could potentially revolutionize therapeutic approaches. Recent investigations have highlighted intricate interactions among genetic, molecular, and environmental factors in AD. Optimism arises from neurobiological advancements and diverse treatment options, potentially slowing or halting disease progression. Amyloid-beta plaques and tau protein tangles crucially influence AD onset and progression. Emerging treatments involve diverse strategies, such as approaches targeting multiple pathways involved in AD pathogenesis, such as inflammation, oxidative stress, and synaptic dysfunction pathways. Clinical trials using humanized monoclonal antibodies, focusing on immunotherapies eliminating amyloid-beta, have shown promise. Nonpharmacological interventions such as light therapy, electrical stimulation, cognitive training, physical activity, and dietary changes have drawn attention for their potential to slow cognitive aging and enhance brain health. Precision medicine, which involves tailoring therapies to individual genetic and molecular profiles, has gained traction. Ongoing research and interdisciplinary collaboration are expected to yield more effective treatments.

Indexed as

Alzheimer DiseaseAcetylcholineAmyloidCholesterolExosomesGlucoseGlucose Transport Proteins, FacilitativeHumansImmunotherapyNeurobiologyNeurovascular CouplingOxidative StressPhototherapyPrecision Medicinetau ProteinsAcetylcholineAmyloidCholesterolGlucoseGlucose Transport Proteins, Facilitativetau ProteinsAlzheimer’s disease (AD)Amyloid-beta (Aβ)Amyloid precursor protein (APP)Aβ protofibrilsNeurofibrillary tangles (NFTs)Tau protein

Identifiers

PMID39102108

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.